{"favorite_id": 10130, "calc_type": "calculator", "dosing": false, "full_title_en": "Tokyo Guidelines for Acute Cholecystitis 2018", "short_title_en": "Tokyo Guidelines 2018 (Acute Cholecystitis)", "medium_description_en": "<span id=\"docs-internal-guid-21529dff-7fff-2c70-b4de-fd0bd3116dfb\">Provides diagnostic criteria and severity grading for acute cholecystitis.</span>", "short_description_en": "Acute cholecystitis diagnosis and grading.", "before_use": "", "instructions_en": "", "purpose_en": ["Diagnosis"], "disease_en": ["Cholecystitis"], "specialty_en": ["Surgery (General)", "Hospitalist Medicine", "Internal Medicine", "Gastroenterology", "Critical Care"], "chief_complaint_en": ["Abdominal Pain", "Vomiting"], "system_en": ["Gastrointestinal"], "search_abbreviation_en": ["laparoscopic cholecystectomy", "gallbladder inflammation", "gallbladder", "Cholecystectomy"], "slug": "tokyo-guidelines-acute-cholecystitis-2018", "seo": {"meta_description_en": "The Tokyo Guidelines for Diagnosis and Severity Grading of Acute Cholecystitis provides diagnostic criteria and severity grading for acute cholecystitis.", "keywords_en": "Cholecystectomy, laparoscopic cholecystectomy, gallbladder, gallbladder inflammation"}, "content": {"how_to_use": {"use_case_en": "<p><span id=\"docs-internal-guid-46f2ae1b-7fff-1078-b5aa-fc5d6e207b43\">Use in patients with suspected acute cholecystitis (i.e., right upper quadrant tenderness, liver enzyme abnormalities, imaging findings characteristic of acute cholecystitis).</span></p>", "pearls_pitfalls_en": "<p><span id=\"docs-internal-guid-e187751d-7fff-5895-4d63-329627b94a0c\"></span></p>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">More extensively validated in non-US populations.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Conditions such as acute hepatitis and acute cholangitis may have some similarities in presentation and should be excluded, as well as chronic cholecystitis.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Measurement of serum procalcitonin has <em>not</em> been shown to be useful for diagnosis or severity grading.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">If ultrasound is non-diagnostic, cholescintigraphy (HIDA) has a high sensitivity and specificity for diagnosis of acute cholecystitis. CT has low specificity.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Laparoscopic cholecystectomy (LC) to treat moderate- and severe-grade acute cholecystitis (Grades II and III) has better clinical outcomes at high volume centers.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The guidelines recommend using the <calculator id=\"3917\">Charlson Comorbidity Index (CCI)</calculator> and <calculator id=\"10024\">ASA Physical Status</calculator> to stratify patients into low risk and high risk surgical candidates.</p>\n</li>\n</ul>", "why_use_en": "<p><span id=\"docs-internal-guid-d5dea6e3-7fff-7ac4-bcf2-c03d497da0a2\">Objectively guides diagnosis and management of patients with acute cholecystitis in terms of early or delayed surgical intervention, early or delayed gallbladder drainage, and antibiotic choice and duration.</span></p>"}, "next_steps": {"advice_en": "<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">If a definitive diagnosis cannot be made on presentation, it is reasonable to reassess the patient using the diagnostic criteria every 6-12 hours.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Early LC in 3-7 days is recommended for low risk candidates.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">For high risk candidates, percutaneous transhepatic gallbladder drainage should be considered. Endoscopic drainage (either via <abbr title=\"Endoscopic ultrasound\">EUS</abbr> or <abbr title=\"Endoscopic retrograde cholangiopancreatography\">ERCP</abbr>) can be considered in high volume centers.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Antibiotics should be chosen based on severity of disease, location of infection (community or hospital acquired), and local susceptibilities (see <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/29090866\" target=\"_blank\">Tokyo Guidelines 2018 Antimicrobial Therapy for Acute Cholangitis and Cholecystitis</a>).</p>\n</li>\n</ul>", "management_en": "<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Grade I (mild):</p>\n</li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">LC should ideally be performed early after onset of symptoms for low risk patients based on the <calculator id=\"3917\">CCI</calculator> and <calculator id=\"10024\">ASA</calculator> scores.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">For high risk patients (<calculator id=\"3917\">CCI</calculator> &ge;6, <calculator id=\"10024\">ASA</calculator> &ge;3), conservative treatment can be considered initially (antibiotics, supportive care), with LC once clinical response achieved.</p>\n</li>\n</ul>\n</ul>\n<p><span id=\"docs-internal-guid-b5bf4107-7fff-ea55-a8e1-9ef2df2c62f6\"></span></p>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Grade II (moderate):</p>\n</li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">LC should ideally be performed early after onset of symptoms for low risk patients based on the <calculator id=\"3917\">CCI</calculator> and <calculator id=\"10024\">ASA</calculator>&nbsp;scores, preferably in a high volume center.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">In high risk patients (<calculator id=\"3917\">CCI</calculator> &ge;6, <calculator id=\"10024\">ASA</calculator> &ge;3), gallbladder drainage should be considered early with delayed/elective LC.</p>\n</li>\n</ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Grade III (severe):</p>\n</li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Resuscitative measures should be initiated at first with antibiotics, fluid resuscitation and vasopressor/respiratory support as needed.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">When considering LC, note negative predictive factors of neurological dysfunction, respiratory dysfunction, and co-existence of jaundice (total bilirubin &ge;2 mg/dL). In addition, scores of <calculator id=\"3917\">CCI</calculator> &ge;4 and <calculator id=\"10024\">ASA</calculator> &ge;3 suggest high risk for LC.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">If an adequate clinical response is achieved in low risk patients, early LC can be considered in a high volume expert center.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">In high risk patients, or all patients in low volume centers, early gallbladder drainage is recommended, especially if it is not possible to control gallbladder inflammation with initial treatment.</p>\n</li>\n</ul>\n</ul>", "critical_actions_en": ""}, "about": {"formula_en": "<p dir=\"ltr\"><span id=\"docs-internal-guid-30f7df92-7fff-88cc-e5e1-6f03c7c83b41\">Patient must have a suspected diagnosis (&ge;1 item in A + &ge;1 item in B or C) or definite diagnosis (&ge;1 item in A, B, and C) to meet entry criteria for severity grading, see table below:</p>\n<p dir=\"ltr\"><strong>Diagnosis:</strong></p>\n<div dir=\"ltr\">\n<table><colgroup><col width=\"173\" /><col width=\"275\" /></colgroup>\n<tbody>\n<tr>\n<td colspan=\"2\">\n<p dir=\"ltr\"><strong>Criteria</strong></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\">\n<p dir=\"ltr\"><strong>Part A</strong></p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"2\">\n<p dir=\"ltr\">Local signs of inflammation</p>\n</td>\n<td>\n<p dir=\"ltr\">Murphy's sign</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Right upper abdominal quadrant mass, pain, or tenderness</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\">\n<p dir=\"ltr\"><strong>Part B</strong></p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"3\">\n<p dir=\"ltr\">Systemic signs of inflammation</p>\n</td>\n<td>\n<p dir=\"ltr\">Fever</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Elevated CRP</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Elevated WBC count</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\">\n<p dir=\"ltr\"><strong>Part C</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Imaging</p>\n</td>\n<td>\n<p dir=\"ltr\">Imaging findings characteristic of acute cholecystitis*</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p dir=\"ltr\">*e.g. pericholecystic fluid, gallstones/debris.</p>\n<p dir=\"ltr\">&nbsp;</p>\n<p dir=\"ltr\"><strong>Severity grading:</strong></p>\n<div dir=\"ltr\">\n<table><colgroup><col width=\"*\" /></colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>Grade III (dysfunction in &ge;1 of the following):</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Cardiovascular dysfunction: hypotension requiring treatment with dopamine &ge;5 &mu;g/kg per min or any dose of norepinephrine</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Neurological dysfunction: decreased level of consciousness</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Respiratory dysfunction: PaO<sub>2</sub>/FiO<sub>2</sub> ratio &lt;300</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Renal dysfunction: oliguria or creatinine &gt;2.0 mg/dL</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Hepatic dysfunction: <abbr title=\"Prothrombin time - International normalized ratio\">PT\u2010INR</abbr> &gt;1.5</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Hematological dysfunction: platelet count &lt;100,000/mm<sup>3</sup></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>Grade II (&ge;1 of the following conditions):</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Elevated WBC count (&gt;18,000/mm<sup>3</sup>)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Palpable tender mass in the right upper abdominal quadrant</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Duration of complaints &gt;72 hours</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Marked local inflammation (gangrenous cholecystitis, pericholecystic abscess, hepatic abscess, biliary peritonitis, emphysematous cholecystitis)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>Grade I</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Acute cholecystitis does not meet the above criteria; no organ dysfunction and mild inflammatory changes in the gallbladder</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p></p>", "more_info_en": "<p dir=\"ltr\">Interpretation:</p>\n<div dir=\"ltr\">\n<table><colgroup><col width=\"98\" /><col width=\"228\" /><col width=\"123\" /></colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>Grade</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>Acute cholecystitis severity</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>30day mortality</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">I</p>\n</td>\n<td>\n<p dir=\"ltr\">Mild</p>\n</td>\n<td>\n<p dir=\"ltr\">1.1%</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">II</p>\n</td>\n<td>\n<p dir=\"ltr\">Moderate</p>\n</td>\n<td>\n<p dir=\"ltr\">0.8%</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">III</p>\n</td>\n<td>\n<p dir=\"ltr\">Severe</p>\n</td>\n<td>\n<p dir=\"ltr\">5.4%</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p><span id=\"docs-internal-guid-4188c02f-7fff-499e-1047-5214fa767c04\"><span id=\"docs-internal-guid-4188c02f-7fff-499e-1047-5214fa767c04\">Note: decrease in mortality for moderate severity is counterintuitive, but reflects limitations in the data.<br /></p>", "evidence_based_medicine_en": "<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The <a href=\"https://onlinelibrary.wiley.com/doi/full/10.1002/jhbp.515\" target=\"_blank\">Tokyo Guidelines 2018 (TG18)</a> are a revision of the 2013 guidelines (TG13), and incorporate new evidence based on validation studies of TG13.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/28419779\" target=\"_blank\">Yokoe et al (2017)</a> studied 4,360 patients and found that the 30-day overall mortality rate was 1.1% for Grade I, 0.8% for Grade II, 5.4% for Grade III (p &lt;0.001), and the higher the grade, the more likely open surgery would be selected (p &lt;0.001).</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/26288122\" target=\"_blank\">Wright et al (2015)</a> studied 445 patients, in the first study validating&nbsp;Tokyo Guidelines&nbsp;in American patients, and found that length of stay (p &lt;0.001), disposition to home (p &lt;0.001), and morbidity (p = 0.003) correlated with increasing TG13 grade.</p>\n</li>\n</ul>", "references_list": {"Original/Primary Reference": [{"href": "https://onlinelibrary.wiley.com/doi/full/10.1002/jhbp.515", "text": "Yokoe M, Hata J, Takada T, et al. Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholecystitis (with videos). J Hepatobiliary Pancreat Sci. 2018;25(1):41-54."}], "Other References": [{"href": "https://www.ncbi.nlm.nih.gov/pubmed/26288122", "text": "Wright GP, Stilwell K, Johnson J, Hefty MT, Chung MH. Predicting length of stay and conversion to open cholecystectomy for acute cholecystitis using the 2013 Tokyo Guidelines in a US population. J Hepatobiliary Pancreat Sci. 2015;22:795-801."}, {"href": "https://www.ncbi.nlm.nih.gov/pubmed/28419779", "text": "Yokoe M, Takada T, Hwang TL, Endo I, Akazawa K, Miura F, et al. Validation of TG13 severity grading in acute cholecystitis: Japan\u2010Taiwan collaborative study for acute cholecystitis. J Hepatobiliary Pancreat Sci. 2017;24:338-45."}, {"href": "https://www.ncbi.nlm.nih.gov/pubmed/29090866", "text": "Gomi, H, et al. Tokyo Guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Sci. 2018;25:3-16."}], "Validation": [{"href": "", "text": ""}], "Clinical Practice Guidelines": [{"href": "", "text": ""}], "Manufacturer Website": [{"href": "", "text": ""}], "Outcomes": [{"href": "", "text": ""}]}}, "contributor": {"expert_name": [{"description": "<p>Joseph Mizrahi, MD, is an internal medicine resident at Stony Brook University Hospital in New York. Born and raised in Brooklyn, New York, Dr. Mizrahi received his medical degree from the Sackler School of Medicine at Tel Aviv University, and he is also currently a student at the School of Public Health at Stony Brook University. Dr. Mizrahi's areas of interest include gastroenterology and colorectal cancer prevention and screening.</p>", "firstName": "Joseph", "img": "https://cdn-web-img.mdcalc.com/people/joseph-mizrahi.jpg", "lastName": "Mizrahi", "name": "Joseph Mizrahi, MD", "target": "joseph-mizrahi", "signedCOI": true, "hasDisclosure": []}]}, "reviewer": {"expert_name": [{"name": "Lionel D'Souza, MBBS"}]}, "creator": [{"name": "Dr. Masamichi Yokoe", "creator_info": {"about_en": "Masamichi Yokoe, MD, is a physician in the internal medicine department at Nagoya Daini Red Cross Hospital in Honshu, Japan. Dr. Yokoe's primary research is focused on management of acute cholangitis and cholecystitis.", "pubmedLink": "https://www.ncbi.nlm.nih.gov/pubmed/?term=Yokoe%20M%5BAuthor%5D&cauthor=true&cauthor_uid=22872303"}}], "related_resources": {"mdcalc_rating": {"evidence": "", "clinical": "", "popularity": ""}, "guidelines": [], "teaching": [], "videos": [], "interests": [], "partner_contact": [], "sdm_tool": []}}, "input_schema": [{"type": "subheading", "subheading": "Part A: Local Signs of Inflammation", "subheading_instructions": ""}, {"type": "toggle", "label_en": "Murphy's sign", "name": "sign", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "", "show_points": false, "default": 0, "optional": false}, {"type": "toggle", "label_en": "Right upper abdominal quadrant mass, pain, or tenderness", "name": "mass", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "", "show_points": false, "default": 0, "optional": false}, {"type": "subheading", "subheading": "Part B: Systemic Signs of Inflammation", "subheading_instructions": ""}, {"type": "toggle", "label_en": "Fever", "name": "fever", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "", "show_points": false, "default": 0, "optional": false}, {"type": "toggle", "label_en": "Elevated CRP", "name": "crp", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "", "show_points": false, "default": 0, "optional": false}, {"type": "toggle", "label_en": "Elevated WBC count", "name": "wbc", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "", "show_points": false, "default": 0, "optional": false}, {"type": "subheading", "subheading": "Part C: Imaging", "subheading_instructions": ""}, {"type": "toggle", "label_en": "Imaging findings characteristic of acute cholecystitis", "name": "image", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "", "show_points": false, "default": 0, "tips_en": "e.g. pericholecystic fluid, gallstones/debris", "optional": false}, {"type": "subheading", "subheading": "Grading", "subheading_instructions": ""}, {"type": "toggle", "label_en": "Cardiovascular dysfunction", "name": "cardio", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "(sign + mass) > 0 && ((fever + crp + wbc) > 0 || image > 0)", "show_points": false, "default": 0, "tips_en": "Hypotension requiring treatment with dopamine \u22655 \u03bcg/kg per min or any dose of norepinephrine", "optional": false}, {"type": "toggle", "label_en": "Neurological dysfunction", "name": "neuro", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "(sign + mass) > 0 && ((fever + crp + wbc) > 0 || image > 0)", "show_points": false, "default": 0, "tips_en": "Decreased level of consciousness", "optional": false}, {"type": "toggle", "label_en": "Respiratory dysfunction", "name": "resp", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "(sign + mass) > 0 && ((fever + crp + wbc) > 0 || image > 0)", "show_points": false, "default": 0, "tips_en": "PaO<sub>2</sub>/FiO<sub>2</sub> ratio <300", "optional": false}, {"type": "toggle", "label_en": "Renal dysfunction", "name": "renal", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "(sign + mass) > 0 && ((fever + crp + wbc) > 0 || image > 0)", "show_points": false, "default": 0, "tips_en": "Oliguria or creatinine >2.0 mg/dL", "optional": false}, {"type": "toggle", "label_en": "Hepatic dysfunction", "name": "hep", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "(sign + mass) > 0 && ((fever + crp + wbc) > 0 || image > 0)", "show_points": false, "default": 0, "tips_en": "<abbr title = \"Prothrombin time test\">PT\u2010INR</abbr> >1.5", "optional": false}, {"type": "toggle", "label_en": "Hematological dysfunction", "name": "hem", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "(sign + mass) > 0 && ((fever + crp + wbc) > 0 || image > 0)", "show_points": false, "default": 0, "tips_en": "Platelet count <100,000/mm<sup>3</sup>", "optional": false}, {"type": "toggle", "label_en": "Elevated WBC count", "name": "wbc18", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "(sign + mass) > 0 && ((fever + crp + wbc) > 0 || image > 0)", "show_points": false, "default": 0, "tips_en": ">18,000/mm<sup>3</sup>", "optional": false}, {"type": "toggle", "label_en": "Palpable tender mass in the right upper abdominal quadrant", "name": "mass18", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "(sign + mass) > 0 && ((fever + crp + wbc) > 0 || image > 0)", "show_points": false, "default": 0, "optional": false}, {"type": "toggle", "label_en": "Duration of complaints >72 hours", "name": "duration", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "(sign + mass) > 0 && ((fever + crp + wbc) > 0 || image > 0)", "show_points": false, "default": 0, "optional": false}, {"type": "toggle", "label_en": "Marked local inflammation", "name": "local", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "(sign + mass) > 0 && ((fever + crp + wbc) > 0 || image > 0)", "show_points": false, "default": 0, "tips_en": "Gangrenous cholecystitis, pericholecystic abscess, hepatic abscess, biliary peritonitis, emphysematous cholecystitis", "optional": false}], "md5": "8408bceeea2299aa2db8dc105592f84a", "cmeVersion": "10130.1", "related_calcs": [{"calcId": 10320, "short_title_en": "Rome IV for Gallbladder Disorder", "slug": "rome-iv-diagnostic-criteria-functional-gallbladder-disorder"}, {"calcId": 3314, "short_title_en": "TNM Pancreatic CA Staging", "slug": "tnm-staging-pancreatic-cancer"}, {"calcId": 10178, "short_title_en": "TNM Pancreatic CA Staging (8th Ed.)", "slug": "tnm-staging-pancreatic-cancer-8th-edition"}]}